Thyroid hormones play a crucial role in regulating various physiological processes, including hepatic function. This review article explores the multifaceted actions of thyroid hormones on the liver, encompassing their influence on lipid metabolism, glucose metabolism, drug metabolism, and bile acid synthesis. We will also discuss the impact of thyroid hormone dysfunctions, both hypothyroidism and hyperthyroidism, on hepatic function and the potential therapeutic implications of thyromimetics in liver diseases.
The liver is a vital organ with diverse functions, including metabolism, detoxification, and bile acid synthesis. Thyroid hormones, namely triiodothyronine (T3) and thyroxine (T4), exert profound effects on hepatic function, influencing a wide range of metabolic processes. This review will delve into the intricate mechanisms by which thyroid hormones regulate hepatic function, exploring their impact on key metabolic pathways and their clinical implications.
Thyroid hormone receptors (TRs) are nuclear receptors that bind to thyroid hormones and regulate gene transcription.
TRs are present in various tissues, including the liver, where they regulate the expression of numerous genes involved in metabolic processes.
Upon binding to T3, TRs form heterodimers with retinoid X receptors (RXRs) and bind to specific DNA sequences known as thyroid hormone response elements (TREs).
This interaction leads to the transcriptional activation or repression of target genes, influencing a wide range of cellular processes.
Thyroid hormones stimulate hepatic fatty acid oxidation and ketogenesis, increasing energy expenditure.
They promote cholesterol synthesis and secretion, while also influencing lipoprotein metabolism.
Hypothyroidism is associated with hyperlipidemia, including elevated levels of triglycerides and low-density lipoprotein cholesterol (LDL-C).
Hyperthyroidism, on the other hand, can lead to elevated levels of high-density lipoprotein cholesterol (HDL-C) but also increase the risk of hepatic steatosis.
Thyroid hormones play a crucial role in regulating hepatic glucose output.
They increase hepatic gluconeogenesis and glycogenolysis, leading to increased blood glucose levels.
Hypothyroidism can lead to insulin resistance and impaired glucose tolerance.
Hyperthyroidism can cause hyperglycemia and contribute to the development of diabetes mellitus.
Thyroid hormones can influence the activity of hepatic enzymes involved in drug metabolism, including cytochrome P450 enzymes.
Hyperthyroidism can increase the activity of these enzymes, leading to accelerated drug clearance and potentially decreased drug efficacy.
Hypothyroidism can have the opposite effect, leading to decreased drug metabolism and increased drug levels, potentially increasing the risk of adverse drug reactions.
Thyroid hormones stimulate bile acid synthesis and secretion.
Hypothyroidism can lead to decreased bile acid synthesis and impaired bile flow, potentially contributing to cholestasis.
Understanding the impact of thyroid hormone on hepatic function is crucial for the management of thyroid disorders and the treatment of liver diseases.
Thyroid hormone replacement therapy is essential for patients with hypothyroidism to restore normal hepatic function and prevent complications.
Thyromimetics, synthetic compounds that mimic the actions of thyroid hormones, are being investigated for their potential therapeutic applications in various liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Thyroid hormones play a critical role in regulating various aspects of hepatic function, including lipid metabolism, glucose metabolism, drug metabolism, and bile acid synthesis. Understanding the intricate mechanisms by which thyroid hormones influence these processes is essential for the diagnosis and management of thyroid disorders and for the development of novel therapeutic strategies for liver diseases. Further research is warranted to explore the full spectrum of thyroid hormone action on the liver and its implications for human health.
1.
More Positive Survival Data in Lung Cancer With Perioperative Therapy
2.
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
3.
Study finds 10% of pediatric blood cancers may stem from medical imaging radiation
4.
For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.
5.
Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.
1.
Case Study: Artificial Intelligence in Early Cancer Detection
2.
Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment
3.
What is Mullerian and How Does it Affect Your Health
4.
AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies
5.
Is p53 the Missing Puzzle Piece? Exploring Its Polymorphisms in Cervical Cancer Risk
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Should We Use DARA Up Front As First-Line Therapy in MM?
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation